在ALS的运动衰退之外:以患者为中心的对非运动表现的洞察力
Anca Moțățăianu1,2, Sebastian Andone1,2, Smaranda Maier1,2
1Department of Neurology, University of Medicine, Pharmacy, Science and Technology of Târgu Mureș 'George Emil Palade', 540142 Târgu Mureș, Romania.
Medicina (Kaunas, Lithuania)
|September 27, 2025
概括
非运动性症状在肌缩性侧面硬化症 (ALS) 中很常见,影响睡眠,消化和认知. 这些症状可能会影响生活质量和疾病进展,突出显示需要全面的患者护理.
科学领域:
- 神经学 神经学
- 神经退行性疾病 神经退行性疾病
- 临床医学 临床医学
背景情况:
- 肌缩侧面硬化症 (ALS) 越来越多地被认为超出了运动神经元退化.
- 非运动性症状 (NMS) 显著影响ALS患者的生活质量和预后.
- 了解NMS对于全面了解ALS至关重要.
研究的目的:
- 调查ALS患者非运动症状的患病率和影响.
- 探索特定的NMS与运动功能之间的关联.
- 检查NMS,认知/情感领域和疾病进展之间的关系.
主要方法:
- 评估了44名ALS患者和35名健康对照.
- 使用ALSFRS-R.评估的运动功能.
- 用NMSQuest评估NMS,用FAB评估认知功能,用BDI评估抑郁症.
主要成果:
- 大多数ALS患者出现了NMS.
- 特定的NMS与运动子值相关 (例如,睡眠与精细运动,消化与柱).
- 尿路症状与进展缓慢相关;认知/情感问题与功能表现差相关.
结论:
- 在ALS中,非运动性症状非常普遍.
- 随着尿路和感官症状的出现,NMS可以独立于运动衰退而发生.
- 认知,情感和行为变化与运动症状并存,影响整体功能.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
363
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
363
Dementia
523
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
523
Parkinson's Disease: Treatment
986
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
986


